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Cancer cells outwit the immune system 
long before they debut as visible tumors, 
say Willimsky et al. (page 1687).
Despite a wealth of studies, researchers 
still don’t know when the immune sys-
tem is alerted to the presence of cancer 
cells or when its response is subverted. 
Part of the problem stems from the fact 
that T cell responses in most animal models 
are tracked only after tumors form.
To get an earlier start, Willimsky et al. 
designed a mouse model in which a gene 
silencer was inserted near an oncogene. 
When a random mutation disabled the 
silencer, the mice expressed the oncogene 
and eventually developed cancer. These 
mice could be identified by the presence 
of antioncogene antibodies, which ap-
peared before tumors formed. The pres-
ence of antibodies indicated an activated 
immune system, allowing the authors to 
study T cell responses as the earliest possible 
time during cancer development.
The researchers now find that the 
T cells fail months before tumors appear. 
Antitumor antibodies often appeared by 
six months of age, at which point the 
T cells were already disabled. Tumors 
became visible about nine months later. 
As the T cells were unable to keep the 
cancer cells at bay, the lag until tumor 
formation might instead stem from the 
requisite time needed to accumulate 
additional, proliferation-inducing muta-
tions. The growing tumors did not lose 
their ability to elicit a T cell response, as 
injecting them into precancerous mice 
provoked tumor rejection.
As tumors grew, the defect in cancer-
specific T cells spread to all cytotoxic T 
cells. Proponents of past tumor models 
attributed this generalized apathy to a 
threshold level of tumor-derived, T cell-
inhibiting molecules 
that increase as a func-
tion of tumor size. The 
authors ruled out this 
idea by engineering 
mice that expressed the 
oncogene during em-
bryogenesis. T cells in 
these mice treated the 
oncogene as “self” and 
thus allowed tumors 
to grow unchecked. These tumors did 
not, however, hamper the ability of 
other T cells to recognize foreign 
antigens.
Others have blamed the generalized 
T cell defects on the suppressive cytokine 
TGF-β and/or a population of immature 
myeloid cells that inhibit T cells in vitro. 
Indeed, mice that turned on the cancer 
gene had high TGF-β levels and grow-
ing numbers of immature myeloid cells 
at the time they had developed anti-
tumor antibodies. How oncogene-
  induced antibody responses might lead 
to TGF-β production and myeloid cell 
growth remains to be seen. 
STIM1 strengthens clotting
On page 1583, Varga-Szabo et al. show that platelets missing a calcium channel opener 
build puny, feeble clots that may actually save lives.
Platelets require calcium to initiate clotting in response to extracellular cues. When 
calcium is needed, most cells first deplete their ER stores. This depletion is sensed by an ER 
protein called STIM1, which sits near enough to the plasma membrane to open up calcium 
channels on the cell surface. But since platelets have only stunted ER-like tubules, they 
were thought to rely instead on an activation-induced lipid, which opens surface calcium 
channels independently of internal stores.
Platelets also have plenty of STIM1, however, which Varga-Szabo et al. now show is 
needed for slow-but-steady clot formation. Activated STIM1-deficient platelets, the authors 
found, did not accumulate calcium from external sources.
Internal calcium stores in the mutant platelets were sufficient for rapid clot formation in 
response to short-lived ligands such as thrombin. But platelets needed STIM1-induced 
calcium influx to clot in response to collagen on injured vessels, which triggers a slower 
signaling pathway. In the absence of STIM1, clots were small and disintegrated easily, 
particularly under conditions that mimicked blood flow. The defective platelets continually 
broke away from the clots, suggesting that STIM1 helps make platelets stickier.
The results suggest that a quick calcium burst from ER-like tubules might be sufficient to 
build small clots to patch up a minor tear. The STIM1-driven calcium spike, on the other 
hand, might be necessary to form larger clots under high shear, as occurs in small or fat-clogged vessels.
Mice lacking STIM1 were protected from injury-induced vessel blockage and strokes, as their feeble clots allowed 
some blood to flow into injured brain tissues. As the clotting problem didn’t prolong bleeding, a small, transient clot 
might be all that’s needed to prevent hemorrhage, with the added bonus of avoiding a complete halt in blood flow. 
Large tumors (circles) appear more than a year after mice turn 
on an oncogene, long after T cells are disabled.
Vessel-blocking clots (top) are avoided 
when platelets lack STIM1 (bottom).
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